

REMARKS

Claims 6-12 are pending in the application. Support for new claims 6-11 can be found throughout the specification. In particular, support for new claims 6 and 12 can be found at pages 25-29 in the specification. Support for new claim 7 can be found at page 19 in the specification. Support for new claim 8 can be found at pages 13 and 30-31 in the specification. Support for new claim 9 can be found at page 11 in the specification. Support for new claims 10 and 11 can be found at pages 31-34 and 34-35, respectively, in the specification. Accordingly, no new matter has been inserted into the application.

Objection

Claims 4 and 5 have been objected to because the phrase “any one” is misspelled as “anyone”. Claims 4 and 5 have been canceled and the presently pending claims do not recite “anyone.”

Accordingly, this objection has been overcome.

Rejection Under 35 U.S.C. §112, First Paragraph

Claims 1-5 have been rejected under 35 U.S.C. §112, first paragraph as failing to comply with the enablement requirement. Applicants traverse this rejection. Reconsideration and withdrawal thereof are respectfully requested.

The Examiner states that the specification is enabling for treating arthritis. However, the Examiner states that the specification does not reasonably provide enablement for the prevention of arthritis. Although Applicants do not agree with the Examiner, Applicants note that currently pending claims are directed to treating arthritis. Thus, Applicants submit that the

present application provides a fully enabling description of the presently claimed invention.

Accordingly, it is believed that this rejection has been overcome.

Rejection Under 35 U.S.C. §102(b) over Lin (CN 14188690A)

Claims 1-5 have been rejected under 35 U.S.C. §102(b) as being anticipated by Lin. Applicants traverse this rejection. Reconsideration and withdrawal thereof are respectfully requested.

Presently claimed invention

The presently claimed invention is directed to compositions comprising butanol fraction of extract of *Notoginseng radix* extracted by water, ethanol or a mixed solvent of water, and a method of treating arthritis by administering the composition to a subject.

Lin

Lin discloses a composition extracted from notoginseng by ethyl alcohol and n-butanol. However, Lin fails to disclose or suggest compositions comprising butanol fraction of extract of *Notoginseng radix* extracted by water, ethanol or a mixed solvent of water and a method of treating arthritis by administering the composition to a subject as in the presently claimed invention.

Distinctions of the presently claimed invention over Lin

Lin discloses a composition comprising ethanol and butanol extract of a root of *Notoginseng radix* and the use of the composition for preventing and curing angiocardopathy and cerebrovascular disease.

However, the presently claimed invention is directed to a composition comprising butanol fraction of extract of *Notoginseng radix* and a method of using the inventive composition to treat arthritis. Therefore, Lin fails to disclose or suggest a composition comprising butanol fraction of extract of *Notoginseng radix* and a method of using the inventive composition to treat arthritis as in the presently claimed invention. Accordingly, Lin fails to anticipate the presently claimed invention.

Rejection Under 35 U.S.C. §102(b) over Cui (CN 1348796A)

Claims 1-5 have been rejected under 35 U.S.C. §102(b) as being anticipated by Cui. Applicants traverse this rejection. Reconsideration and withdrawal thereof are respectfully requested.

Cui

Cui discloses a composition prepared by extracting various plants including radix notoginseng by using ethyl alcohol and then adding boneol into the extract. However, Cui fails to disclose or suggest compositions comprising butanol fraction of extract of *Notoginseng radix* extracted by water, ethanol or a mixed solvent of water and a method of treating arthritis comprising administering the composition to a subject as in the presently claimed invention.

Distinctions of the presently claimed invention over Cui

Cui discloses a pain treating composition prepared by first extracting various plants.

However, the presently claimed invention is directed to a composition comprising butanol fraction of extract of *Notoginseng radix* and a method of using the inventive composition to treat arthritis. Therefore, Cui fails to disclose or suggest a composition

comprising butanol fraction of extract of *Notoginseng radix* and a method of using the inventive composition to treat arthritis as in the presently claimed invention. Accordingly, Cui fails to anticipate the presently claimed invention.

Rejection Under 35 U.S.C. §102(b) over Liu (U.S. Patent No. 4,755,504)

Claims 1-5 have been rejected under 35 U.S.C. §102(b) as being anticipated by Liu. Applicants traverse this rejection. Reconsideration and withdrawal thereof are respectfully requested.

Liu

Liu discloses a composition containing saponin (80-95.5 wt%) and quercetin (0.5-20 wt%), derived from root Tienchi, the Chinese name of *Panax notoginseng*. However, Liu fails to disclose or suggest compositions comprising butanol fraction of extract of *Notoginseng radix* extracted by water, ethanol or a mixed solvent of water and a method of treating arthritis by administering the composition to a subject as in the presently claimed invention.

Distinctions of the presently claimed invention over Liu

Liu discloses a composition containing saponin and quercetin, derived from Tienchi. Apparently, the composition of Liu is effective in treatment of circulatory disease.

However, the presently claimed invention is directed to a composition comprising butanol fraction of extract of *Notoginseng radix* and a method of using the inventive composition to treat arthritis. Therefore, Liu fails to disclose or suggest a composition comprising butanol fraction of extract of *Notoginseng radix* and a method of using the inventive

composition to treat arthritis as in the presently claimed invention. Accordingly, Liu fails to anticipate the presently claimed invention.

Conclusion

It is believed that the application is now in condition for allowance. Applicant requests the Examiner to issue a notice of Allowance in due course. The Examiner is encouraged to contact the undersigned to further the prosecution of the present invention.

The Commissioner is authorized to charge JHK Law's Deposit Account No. 502486 for any fees required under 37 CFR §§1.16 and 1.17 that are not covered, in whole or in part, by a credit card payment enclosed herewith and to credit any overpayment to said Deposit Account No. 502486.

Respectfully submitted,

JHK Law

Dated: May 8, 2007

By: /Joseph Hyosuk Kim/
Joseph Hyosuk Kim, Ph.D.
Reg. No. 41,425

P.O. Box 1078
La Canada, CA 91012-1078
(818)249-8177 – direct; (818)249-8277 – fax